Patrick Forde, MD, has a lot of experience running clinical trials. At any given time, he is running five to ten active clinical trials for patients with lung cancer at Johns Hopkins University. These trials span the full spectrum from early-stage to metastatic lung cancer. The majority of the trials he runs involve the use of immunotherapy drugs—drugs that leverage our natural immune system to combat disease.
In spite of mostly-successfully not being preoccupied with my condition/circumstances/disease, when a lung cancer survivor dies, even one with whom I've had minimal contact; one whom I could barely call an acquaintance, the link in the chain that makes all of us lung cancer patients/survivors stronger is most definitely effected.
Each year Viswam Nair, MD, manages treatment plans for hundreds of patients at Stanford University. A pulmonologist with formal training in epidemiology, Dr. Nair stays current on the latest scientific breakthroughs to offer his patients the best possible outcomes.
Targeted therapies continue to be an important treatment option for those patients whose tumors test positive for an actionable mutation for which a drug exists.
